Login to Your Account

Thesan series B garners $49M for skin therapies; keeps mum on pipeline

By Randy Osborne
Staff Writer

Monday, February 24, 2014

Thesan Pharmaceuticals Inc. followed up last fall’s $16 million series A financing with $49 million in series B money to support research in acne and atopic dermatitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription